Initial treatmerit: diabetic control
Non-insulin-dependent diabetes is a disorder of insulin metabolism. As reviewed by other contributors to this Colloquium, insulin affects both glucose and triacylglycerol metabolism. Since triacylglycerols are an integral part of lipoproteins, lipoprotein metabolism is altered. Increased production rates and decreased fractional clearance rates, as well as changes in lipoprotein composition, may be found.
For this reason, the first step in the treatment of diabetic dyslipidaemia is to improve the underlying derangement in insulin metabolism. This may be broken down into three components: ( 1 ) weight loss, (2) adherence to a diabetic diet and (3) adjustment of insulin or oral hypoglycaemic agcnts to improve fasting blood sugar.
(1) Weight loss. Clinically, weight loss, or a hypocaloric diet without achieving ideal body weight, will improve diabetic control, presumably by reducing the resistance to the peripheral action of insulin [4, 5] .
( 2 ) Adherence to u diabetic diet. The exchange diet recommended by the American Diabetes Association allows the patient to plan the distribution of total calories and sources of calories (fat, protein, carbohydrate) over the day. A more even distribution of calories (bc they fat or carbo- Beyond the distribution of daily calories, the optimum diet for diabetics has yet to be determined. High-carbohydrate diets (55-70% of calories from carbohydrate, with less than 25% of calories from fat) have been reported to be well tolerated in mild diabetics [S, 91. These diets, however, are known to decrease HDL cholesterol levels in normal subjects [lo] , and this decreased HDL is a common dyslipidaernia among diabetics [ 1 I]. High-carbohydrate diets lead to higher postprandial glucose levels and high fasting triacylglycerol levels [ 121. Supporters of this diet, however [ 131, maintain that high-carbohydrate diets reduce the risk for cardiovascular disease, and reduce the fasting non-esterified fatty acid levels (which are higher than normal even in controlled diabetics).
There is new evidence that disputes the claim that high-fat diets (35-40% calories from fat, 40-50% calories from carbohydrate) necessarily lead to higher rates of coronary disease. Epidemiological evidence supports the fact that diets high in fat but low in saturated fatty acids (such as those consumed in the Mediterranean region) are associated with low rates of coronary disease [14] . Recent research has reemphasized a less known fact of previous dietary research that monounsaturated fatty acids are equivalent to carbohydrate with respect to their potential for lowering lowdensity lipoprotein (LDL) cholesterol [ lo]. Since foods high in monounsaturated fatty acids are limited (olives, avocados, peanuts), a high-fat diet low in saturates (less than 10% of calories) did not seem feasible to many people. However, additional research has demonstrated that a common saturated fatty acid (C,,, stearic acid) is converted to a monounsaturated fatty acid shortly after absorption, and that the increase in LDL cholesterol levels seen with other saturated fatty acids of the CI2-C,, variety does not occur with stearic acid [15] . This later finding allows further expansion of acceptable, high-fat food choices, since stearic acid comprises more than one-third of the saturates in beef and pork.
High-fat diets that are low in saturated fatty acids appear to be well tolerated in diabetics and may lead to improved glucose control, decreased fasting triacylglycerol and increased HDL cholesterol level? [ 121. The significance of an increase in non-esterified fatty acids seen in this type of diet has yet to be balanced against thcse positive effects in the research setting.
(3) Adjirstment of hypoglycuemic agents t o improve diabetic control. In our experience, the diabetic dyslipidaemia may improve even when the fasting blood sugar is brought from 140 rng/100 ml to less than 120 mg/100 ml. There is no clinical evidcncc that the use of one type or another of glucose-lowering drugs (oral agents versus insulin) is better for lipid lowering if these two treatment programmes provide cquivalent control of fasting blood sugar levels. This further supports the link between dyslipidaemia and blood sugar, and beforc contemplating drug therapy (which will not improve the insulin abnormalities) all efforts should be aimed at the primary cause of thc dyslipidaemia itself.
Drug therupy
Dyslipidaernias may change in character after improved diabetic control (e.g. type V changing to type IV). Using the classifications in Table 1 , and the known effects of common lipid-lowering drugs detailed in Table 2 , treatment of specific dyslipidaemias are discussed below.
Mild hypercholesterolaemia with normal Iriucylglycerol levels. Weight control and control of fasting blood sugar are important components of the appropriate treatment. Weight control is important even in patients who do not have a triacylglycerol disturbance, as it is known that overfeeding in normal subjects leads to a 20 mg/100 ml increase in total cholesterol for the first 20 kg of excess body weight [16] . If weight loss is unsuccessful, the use of typical agents recommended for non-diabetics (nicotinic acid, bile acid sequestrants) may be associated with adverse side effects. Niacin may worsen plasma glucose and uric acid levels. Bile acid sequestrants increase VLDL cholesterol levels, and in diabetics this could potentially lead to a worsening of the dyslipidaemia. We recommend the drug of first choice as bile acid sequestrants, with careful follow-up of fasting triacyl-glycerol levels in 3-6 weeks. If the triacylglycerol concentration is greater than 250 mg/100 ml, we consider the patient to have failed treatment with bile acid sequestrants. The use of hydroxymethylglutaryl-CoA (HMG-CoA) reductase (EC 1.1.1.88) inhibitors in this class of dyslipidaemia should be reserved for patients who have failed to respond to all other treatments.
Type Ilri: high cholesterol levels with normal iriucylglycerol concentrutions. Beyond weight loss, a low-saturated-fat and low-cholesterol diet, and improved diabetic control, cautious use of bile acid sequestrants may improve this disorder in selected patients. HMG-CoA reductase inhibitors may be the preferred treatment, as these agents decrease VLDL levels as well as LDL levels. Our only reservation is that the potential toxicity of this class of drugs in humans is still unknown.
Mixed hyperlipiduerniu (iticlirding type lib). After weight reduction and improved diabetic control, HMG-CoA reductase inhibitors are the drug of choice for mixed hyperlipidaemia. In rare cases where the LDL cholesterol is not increased, fibric acid derivatives with or without low-dose bile acid sequestrants (dose not to exceed 15 g/day) may be effective.
Type 111 hyperlipiduer7iiu. The prcsence of this disorder can be confirmed by apolipoprotein E phenotyping. This disorder is partially due to a defect in the apolipoprotein E.
Particles which rely o n receptor clearance recognizing apolipoprotein E (such as VLDL remnants and chylomicron remnants) have reduced fractional clearance rates if they are rich in the E 2 isoform. Normally. only 10% o f patients homozygous for the E2 isoform express the dyslipidaemia; however. diabetics with this E2/2 phenotype may more commonly express this disease, as over half of the patients with type 111 are obese and have abnormal glucose tolerance tests [17] . The optimum dietary therapy is a low-fat diet, which will reduce the formation of chylomicrons and chylomicron remnants. Drug therapy includes either fibric acid derivatives or HMG-CoA reductase inhibitors.
Type IV hyperlipiduerniu. This disorder may respond immediately to weight loss and improved diabetic control. In our experience, redistribution of calories to give a more constant intake (such as recommended by the exchange diet) can have beneficial effects. Since high-carbohydrate diets may increase triacylglycerol concentrations, we recommend a high-fat diet, but with low saturated fatty acids. HMG-CoA reductase inhibitors are the drugs of choice; fibric acid derivatives may also be effective as long as LDL cholesterol levels are not increased by this therapy.
Type V hyperlipiduerniu. This disorder is most commonly seen in poorly controlled diabetics. Therapy should be aimed at improving diabetic control and, if triacylglycerol concentrations are greater than 1000 mg/100 ml, decreasing the risk for pancreatitis. A low-fat diet, by decreasing the formation of chylomicrons, is helpful particularly during the acute phase of the disorder. Fibric acid derivatives are the drug of choice.
Low H D L cholesierol levels. This may be the most common dyslipidaemia in well-controlled diabetics. Unfortunately, none of the drugs known to increase HDL levels have been effective in diabetics. Niacin may worsen glucose control; fibric acid derivatives and HMG-CoA reductase inhibitors have failed to increase HDL cholesterol levels in diabetics to normal [18, 191. We are left with conservative measures such as weight loss and a high-fat (with low saturated fatty acids) diet.
Nephrotic sytidrotne. The nephrotic syndrome may be accompanied by any of the above dyslipidaemias. The only effective drug treatment for this disorder involves the use of HMG-CoA reductase inhibitors.
C'oriclirsiori
The treatment of diabetic dyslipidaemia is different to that of similar dyslipidaemias in the non-diabetic population. Before beginning drug therapy, emphasis should be placed on weight loss, improved diabetic control, the use of an exchange diet to spread out the timing of calories, and, in some disorders of triacylglycerols and HDL, a carefully selected high-fat diet that is low in saturated fatty acids. The choice of drugs is limited in diabetics. Niacin, becausc of its tcndency to worsen glucose control, cannot be widely used. Bile acid sequestrants can be used only in carefully selected patients who do not develop hypertriglyceridaemia from this treatment. Fibric acid derivatives are effective in lowering triacylglycerol, but in patients with a combined defect may lead to further increases in LDL cholesterol levels. HMGCoA reductase inhibitors, while effective in many of these disorders, must be used with caution until the long-term toxicity of these agents is known.
